Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

MLA

Hu, Bei, et al. “Phase-I and Randomized Phase-II Trial of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin, Etoposide) in Relapsed or Refractory Classical Hodgkin Lymphoma.” Leukemia & Lymphoma, vol. 59, no. 4, Apr. 2018, pp. 863–70. EBSCOhost, https://doi.org/10.1080/10428194.2017.1359741.

APA

Hu, B., Younes, A., Westin, J. R., Turturro, F., Claret, L., Feng, L., Fowler, N., Neelapu, S., Romaguera, J., Hagemeister, F. B., Rodriguez, M. A., Samaniego, F., Fayad, L. E., Copeland, A. R., Nastoupil, L. J., Nieto, Y., Fanale, M. A., & Oki, Y. (2018). Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leukemia & Lymphoma, 59(4), 863–870. https://doi.org/10.1080/10428194.2017.1359741

Chicago

Hu, Bei, Anas Younes, Jason R Westin, Francesco Turturro, Linda Claret, Lei Feng, Nathan Fowler, et al. 2018. “Phase-I and Randomized Phase-II Trial of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin, Etoposide) in Relapsed or Refractory Classical Hodgkin Lymphoma.” Leukemia & Lymphoma 59 (4): 863–70. doi:10.1080/10428194.2017.1359741.